On Friday, Arcutis Biotherapeutics Inc (NASDAQ: ARQT) was 4.33% up from the session before settling in for the closing price of $8.31. A 52-week range for ARQT has been $1.76 – $13.17.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 303.42%. When this article was written, the company’s average yearly earnings per share was at 59.90%. With a float of $101.75 million, this company’s outstanding shares have now reached $116.89 million.
Considering the fact that the conglomerate employs 296 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 92.17%, operating margin of -136.13%, and the pretax margin is -147.95%.
Arcutis Biotherapeutics Inc (ARQT) Insider Activity
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Arcutis Biotherapeutics Inc stocks. The insider ownership of Arcutis Biotherapeutics Inc is 13.00%, while institutional ownership is 100.50%. The most recent insider transaction that took place on Nov 01 ’24, was worth 86,540. Before that another transaction happened on Oct 01 ’24, when Company’s Director sold 10,000 for $9.26, making the entire transaction worth $92,616. This insider now owns 181,944 shares in total.
Arcutis Biotherapeutics Inc (ARQT) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 59.90% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 9.80% during the next five years compared to -48.07% drop over the previous five years of trading.
Arcutis Biotherapeutics Inc (NASDAQ: ARQT) Trading Performance Indicators
You can see what Arcutis Biotherapeutics Inc (ARQT) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 8.19. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 8.01.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.18, a number that is poised to hit -0.42 in the next quarter and is forecasted to reach -1.14 in one year’s time.
Technical Analysis of Arcutis Biotherapeutics Inc (ARQT)
Compared to the last year’s volume of 3.26 million, its volume of 1.4 million showed lagged in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 39.50%. Additionally, its Average True Range was 0.53.
During the past 100 days, Arcutis Biotherapeutics Inc’s (ARQT) raw stochastic average was set at 28.01%, which indicates a significant decrease from 35.10% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 54.51% in the past 14 days, which was lower than the 68.70% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $9.74, while its 200-day Moving Average is $9.16. Nevertheless, the first resistance level for the watch stands at $9.03 in the near term. At $9.40, the stock is likely to face the second major resistance level. The third major resistance level sits at $9.69. If the price goes on to break the first support level at $8.38, it is likely to go to the next support level at $8.09. Should the price break the second support level, the third support level stands at $7.72.
Arcutis Biotherapeutics Inc (NASDAQ: ARQT) Key Stats
There are 116,891K outstanding shares of the company, which has a market capitalization of 1.06 billion. As of now, sales total 59,610 K while income totals -262,140 K. Its latest quarter income was 30,860 K while its last quarter net income were -52,330 K.
